An in vitro method for determining whether the hepatic fibrosis score of a subject infected with one or more hepatitis viruses has a Metavir fibrotic score of no more than F1 or at least F2, characterized in that it comprises the following steps: 1) in a sample which has been obtained from said subject, measuring the levels to which selected genes are transcribed or translated, said selected genes the levels of transcription or translation of which are measured being the following combination of genes: - SPP1, and - at least one gene from among A2M and VIM, and - at least one gene from among IL8, CXCL10 and ENG, and - zero to sixteen genes from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1, ii) comparing the measuring values of each of said selected genes obtained for said subject with their values, or with the distribution of their values, in reference cohorts which have been pre-established according to their hepatic fibrosis score, said cohorts being: - a cohort of individuals with a hepatic fibrosis which has a Metavir fibrotic score of no more than F1, and - a cohort of individuals with a hepatic fibrosis which has a Metavir fibrotic score of at least F2; in order to classify said subject in whichever of these reference cohorts to which it has the greatest probability of belonging. 1) in a sample which has been obtained from said subject, measuring the levels to which selected genes are transcribed or translated, said selected genes the levels of transcription or translation of which are measured being the following combination of genes: - SPP1, and - at least one gene from among A2M and VIM, and - at least one gene from among IL8, CXCL10 and ENG, and - zero to sixteen genes from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1, ii) comparing the measuring values of each of said selected genes obtained for said subject with their values, or with the distribution of their values, in reference cohorts which have been pre-established according to their hepatic fibrosis score, said cohorts being: - a cohort of individuals with a hepatic fibrosis which has a Metavir fibrotic score of no more than F1, and - a cohort of individuals with a hepatic fibrosis which has a Metavir fibrotic score of at least F2; in order to classify said subject in whichever of these reference cohorts to which it has the greatest probability of belonging. - SPP1, and - at least one gene from among A2M and VIM, and - at least one gene from among IL8, CXCL10 and ENG, and - zero to sixteen genes from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1, ii) comparing the measuring values of each of said selected genes obtained for said subject with their values, or with the distribution of their values, in reference cohorts which have been pre-established according to their hepatic fibrosis score, said cohorts being: ii) comparing the measuring values of each of said selected genes obtained for said subject with their values, or with the distribution of their values, in reference cohorts which have been pre-established according to their hepatic fibrosis score, said cohorts being: - a cohort of individuals with a hepatic fibrosis which has a Metavir fibrotic score of no more than F1, and - a cohort of individuals with a hepatic fibrosis which has a Metavir fibrotic score of at least F2;